

IFW

Patent
Attorney Docket No. 1034284-000003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Patent Application of

Ignacio Blanco Blanco

Application No.: 10/549,759

Filing Date: September 19, 2005

Title: USE OF ALPHA-1 ANTITRYPSIN FOR THE PREPARATION OF MEDICAMENTS FOR THE
TREATMENT OF FIBROMYALGIA



Group Art Unit: 1646

Examiner:

Confirmation No.: 6945

**FIRST
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a FIRST Information Disclosure Statement and accompanying form
PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL PC

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By


Brian P. O'Shaughnessy
Registration No. 32,747

Date: January 27, 2006

Buchanan Ingersoll PC
ATTORNEYS

Including attorneys from Burns Doane Swecker & Mathis

(8/05)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Patent Application of

Ignacio Blanco Blanco

Application No.: 10/549,759

Filed: September 19, 2005

For: USE OF ALPHA-1 ANTITRYPSIN FOR
THE PREPARATION OF
MEDICAMENTS FOR THE
TREATMENT OF FIBROMYALGIA



Group Art Unit: 1646

Examiner:

Confirmation No.: 6945

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BUCHANAN INGERSOLL PC

Date Jan. 27, 2006

By: 
Brian P. O'Shaughnessy
Registration No. 32,747

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620


FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 10/549,759
 Filing Date September 19, 2005
 First Named Inventor Ignacio Blanco Blanco
 Examiner Name
 Attorney Docket Number 1034284-000003

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	4,440,679		Fernandes et al.	04-03-1984
	6,737,405	B2	Roemisch et al.	05-18-2004

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Brantly M., <i>α1-Antitrypsin: Not Just an Antiprotease; Extending the Half-Life of a Natural Anti-Inflammatory Molecule by Conjugation with Polyethylene Glycol</i> , Am J Respir Cell Mol. Biol. (2002) 27:652-645
	Joaquin Esteve-Vives et al., <i>The Spanish Version of the Health Assessment Questionnaire: Reliability, Validity and Transcultural Equivalency</i> Journal of Rheumatology (1993) 20:2116-2112
	Leonard R. Derogatis et al., <i>The SCL-90 and the MMPI: A Step in the Validation of a New Self-Report Scale</i> , Brit. J. Psychiat. (1976) 128:280-289

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.